Pharma Looks to Cash in on Psychedelics as Patients Seek Alternatives to Psychotropic Drugs for Depression

Eli Lilly’s multibillion-dollar acquisition of a company that makes experimental psychedelic therapies marks the largest investment yet by a drugmaker in psychedelic medicine as a treatment for depression. But pharma’s entry into the market raises questions about patents, profits and the future of psychedelic therapy. Eli Lilly’s multibillion-dollar acquisition of AtaiBeckley […] The post Pharma Looks to Cash in on Psychedelics as Patients Seek Alternatives to Psychotropic Drugs for Depression appeared first on Activist Post.

Source: https://www.activistpost.com/pharma-looks-to-cash-in-on-psychedelics-as-patients-seek-alternatives-to-psychotropic-drugs-for-depression/

Author: Editor